Publication follows the Israeli Ministry of Health’s appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19 vaccines
Nes-Ziona, Israel, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that its Chief Scientific Officer, Prof. Dror Mevorach, M.D., and several co-authors published a foundational peer reviewed paper in The New England Journal of Medicine, the world’s most widely read, cited, and influential general medical periodical. The paper, entitled “Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel” was published in collaboration with researchers at several prestigious institutions, including Hadassah Medical Center, University of Jerusalem, Tel Aviv Sourasky Medical Center, the Israel Center for Disease Control, and the Israeli Ministry of Health.
“On behalf of Enlivex, I’d like to congratulate Dror for this impressive accomplishment,” said Dr. Oren Hershkovitz, Chief Executive Officer of Enlivex. “To be appointed by the Israeli Ministry of Health to lead the surveillance of potential side effects related to the Pfizer-BioNTech vaccine, and to have the results of these efforts published in the New England Journal of Medicine, speaks to his position as a leading expert in immunology and the human body’s response to pathogens. Dror’s deep knowledge and understanding of these fields has been critical to our development of Allocetra to-date, and we look forward to further leveraging his skill set as we advance its development as a potential treatment for sepsis, COVID-19, and certain types of cancer.”
Prof. Mevorach commented, “It is an honor to be published in the New England Journal of Medicine, which provides our work with important external validation. I’d like to thank my co-authors as well as the patients who participated in the study for the crucial roles they played in its completion.”
ABOUT THE NEW ENGLAND JOURNAL OF MEDICINE
The New England Journal of Medicine (NEJM) is the most widely read, cited, and influential general medical periodical in the world. More than a million people from nearly every country read NEJM in print and online each week.
Each year, NEJM receives more than 16,000 research and other submissions for consideration for publication. About 5% of original research submissions achieve publication by NEJM; more than half originate from outside the U.S.
NEJM is cited more often in scientific literature than any other medical journal, and has the highest Journal Impact Factor (91.245) of all general medical journals (2020 Journal Impact Factor, Journal Citation Reports, Clarivate, 2021).
AllocetraTM is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or in combination with leading therapeutic agents.
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
ENLIVEX CONTACT Shachar Shlosberger, CFO Enlivex Therapeutics, Ltd. firstname.lastname@example.org
INVESTOR RELATIONS CONTACT Eric Ribner LifeSci Advisors email@example.com